Microdosing in Silicon Valley – between productivity and controversy

In dynamic, high-pressure industries such as technology and startups, where change is constant and expectations are high, some people look for ways to boost creativity, focus and perceived efficiency. One of the ideas that has gained attention in recent years is microdosing psychedelics — especially in places like Silicon Valley. This topic is highly controversial, legally complex and still insufficiently researched, which is why it should always be approached with great caution.

Image by wirestock on Freepik

What is microdosing?

Microdosing is usually described as taking very low doses of psychoactive substances (such as LSD or psilocybin) with the intention of producing subtle psychological or cognitive changes, rather than a full psychedelic experience. In theory, a microdose should be so low that it does not cause clear alterations in perception, hallucinations or strong shifts in consciousness. People who experiment with microdosing often hope for a gentle improvement in mood, creativity or concentration. For a general overview of the idea, see microdosing on Wikipedia.

It is crucial to emphasise that microdosing is not a medically approved treatment method for most conditions, and in many countries — including Poland — the substances typically used in microdosing (such as psilocybin) are illegal. Any self-experimentation with psychoactive compounds can be risky, both legally and health-wise.

Microdosing in Silicon Valley – reported use cases

Media reports and personal accounts suggest that microdosing psilocybin and other psychedelics has become popular in parts of the tech and startup community, particularly in Silicon Valley. Some individuals claim that microdosing helps them work on complex problems, stay motivated for long hours, or navigate high-stress environments. Others say they are looking for support in dealing with emotional struggles or burnout.

Described or self-reported potential benefits include improved mood, a feeling of increased creativity, greater resilience to stress, better sleep quality or a heightened sense of empathy. Some users claim they can focus more deeply on strategic thinking, speed up design processes or feel more open and communicative in business meetings. However, these are subjective reports and not robust clinical data. You can find a broader educational overview in our article psilocybin microdosing – what you need to know.

The topic gained wider visibility after an article by Andrew Leonard in Rolling Stone, which referenced work by psychologist and researcher James Fadiman. Fadiman collected reports from people experimenting with microdosing, including engineers and entrepreneurs, and proposed a structured schedule (often called the “Fadiman protocol”). This is not an officially approved medical guideline and remains outside standard treatment frameworks.

In a culture obsessed with speed and optimisation, “turbocharging” the brain can sound tempting: faster thinking, more ideas, continuous productivity. Yet the key question remains: is this a healthy answer to contemporary pressures, or just another form of overextension? Sometimes slowing down, resting and setting boundaries may be a safer and more sustainable strategy than attempting to chemically boost every aspect of life.

Although there are many anecdotal accounts of microdosing in Silicon Valley, it is still a highly controversial subject. Every nervous system is different, and there is no universal or guaranteed outcome. Anyone considering such practices should first understand the legal situation in their country and, if possible, consult a qualified medical professional rather than rely solely on stories from the internet.

Benefits and risks of psilocybin microdosing

Microdosing psilocybin — taking very small amounts of the compound found in so-called “magic mushrooms” — is often described as a way to access some of the perceived benefits of psychedelics without a full trip. In reality, this approach has both potential upsides and serious limitations, and research is still at an early stage.

Frequently reported potential benefits include:

1. Perceived increase in creativity and productivity. Some people say they find it easier to generate ideas, connect concepts or work on complex tasks.
2. Improved mood and well-being. Users often describe feeling more optimistic, emotionally balanced or resilient, at least in the short term.
3. Enhanced mindfulness and self-awareness. There are reports of people paying more attention to their habits, reactions and emotional patterns.

Even if these effects are experienced by some individuals, they are not guaranteed, may be influenced by expectation (placebo effect) and do not replace evidence-based treatments for mental health conditions.

Risks and limitations include:

1. Unpredictable side effects. Even low doses of psychedelics can, in some people, cause anxiety, restlessness, physiological discomfort or emotional overwhelm. There is no simple way to predict who will react how.
2. Interactions with other medications or conditions. Psilocybin and related compounds can interact with psychiatric medication, cardiovascular conditions or other health issues. Without medical supervision, this can be dangerous.
3. Legal consequences. In many countries, including Poland, psilocybin is illegal. Possession, use or distribution can lead to criminal charges, regardless of the dose or intention.
4. Risk of unhealthy patterns. While classic physical dependence appears unlikely, relying on any substance as a primary way to cope with life can become a psychological crutch and distract from deeper changes that might be needed (therapy, lifestyle, rest).

It is also worth remembering that much of the public conversation about microdosing comes from personal testimonials, popular articles and early-stage research. Large, rigorous clinical trials are still limited. For this reason, conclusions about safety and effectiveness should be drawn with caution, and self-experimentation should not be presented as a harmless trend.

The content on the psychodelicroom.pl website is educational and research-based. We do not encourage the use of any substances that affect consciousness. All psychoactive substances can both help and harm, depending on context, dose and individual vulnerability. In particular, we advise against cultivating mushrooms from growkits in countries where it is illegal — including Poland — because this may involve criminal liability. Growkits purchased in our store are intended solely for research and collection purposes, and we recommend disposing of them within 72 hours of receipt in accordance with local regulations.

Selected further reading (external, in English):

• Financial Times – coverage of microdosing and work culture
• Rolling Stone – How LSD microdosing became the hot new business trip